Cipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on account of lower Albuterol Sulphate sales. Revenue for the quarter is likely to grow at 13% year-on-year (YoY), according to an average estimate of three brokerages, and net profit for the same period is expected to rise around 19% YoY.
Diwali Picks: Praj Inds, Persistent & 10 other top ideas from Angel One
Ahead of the beginning of Diwali, the domestic brokerage firm Angel One has picked up ten stocks across sectors where investors can place bets. These
October 24, 2024